Advances in the Development of Class I Phosphoinositide 3-Kinase (PI3K) Inhibitors

Dima A Sabbah; Jian Hu; Haizhen A Zhong

doi:10.2174/1568026615666150915115823

Advances in the Development of Class I Phosphoinositide 3-Kinase (PI3K) Inhibitors

Curr Top Med Chem. 2016;16(13):1413-26. doi: 10.2174/1568026615666150915115823.

Authors

Dima A Sabbah, Jian Hu, Haizhen A Zhong¹

Affiliation

¹ DSC 362, Department of Chemistry, The University of Nebraska at Omaha, 6001 Dodge Street, Omaha, Nebraska 68182 U.S.A. hzhong@unomaha.edu.

PMID: 26369826
DOI: 10.2174/1568026615666150915115823

Abstract

The PI3K signaling cascade is the key moderator of cell proliferation, survival, motility, and apoptosis. Class I PI3K proteins are well characterized and linked to thrombosis (PI3Kβ), rheumatoid arthritis (PI3Kδ), and cancer (PI3Kα). In this review, we explore the latest progress in the design and development of selective Class I PI3K inhibitors from the perspective of drug design and structure activity relationships.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Drug Design*
Humans
Phosphatidylinositol 3-Kinases / metabolism
Phosphoinositide-3 Kinase Inhibitors*
Protein Kinase Inhibitors / chemistry
Protein Kinase Inhibitors / pharmacology*

Substances

Phosphoinositide-3 Kinase Inhibitors
Protein Kinase Inhibitors